Literature DB >> 12695748

Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity.

Andrew D Blann1, Sukhjinder Marwah, Graham Serjeant, David Bareford, Josh Wright.   

Abstract

Possible pathogenetic processes in sickle cell disease include antioxidants, endothelial and platelet changes, and hypercoagulability. Hypothesizing relationships between these processes, we recruited 47 young adult patients (mean age 19 years) with homozygous sickle cell disease and 40 age-, race- and sex-matched healthy controls and measured plasma markers representative of these processes. We found raised plasma von Willebrand factor (P = 0.001) and intercellular adhesion molecule (P = 0.016, both marking endothelial perturbation, but the latter also marking inflammation), raised soluble P selectin (P = 0.002) (marking platelet activation) and inflammation marker C reactive protein (P = 0.021), but reduced antioxidant capacity (P = 0.002) in patients compared with controls. There was no difference in fibrinogen and there was no significant correlation between any of the indices. Our data suggest that changes in endothelial and platelet function in sickle cell disease are unrelated to reduced antioxidant capacity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695748     DOI: 10.1097/01.mbc.0000061293.28953.8c

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  10 in total

1.  Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.

Authors:  Nalini Raghavachari; Xiuli Xu; Amy Harris; Jose Villagra; Carolea Logun; Jennifer Barb; Michael A Solomon; Anthony F Suffredini; Robert L Danner; Gregory Kato; Peter J Munson; Sidney M Morris; Mark T Gladwin
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

2.  Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.

Authors:  Enrico M Novelli; Gregory J Kato; Margaret V Ragni; Yingze Zhang; Mariana E Hildesheim; Mehdi Nouraie; Suchitra Barge; Michael P Meyer; Andrea Cortese Hassett; Victor R Gordeuk; Mark T Gladwin; Jeffrey S Isenberg
Journal:  Am J Hematol       Date:  2012-02-08       Impact factor: 10.047

3.  The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment.

Authors:  J S Mohan; P L Lip; A D Blann; D Bareford; G Y H Lip
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

4.  Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation.

Authors:  Nayra Cardenes; Catherine Corey; Lisa Geary; Shilpa Jain; Sergey Zharikov; Suchitra Barge; Enrico M Novelli; Sruti Shiva
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

5.  A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.

Authors:  Carolyn Hoppe; Frans Kuypers; Sandra Larkin; Ward Hagar; Elliott Vichinsky; Lori Styles
Journal:  Br J Haematol       Date:  2011-04-08       Impact factor: 6.998

6.  Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.

Authors:  Jeffrey Glassberg; Adeeb H Rahman; Mohammad Zafar; Caroline Cromwell; Alexa Punzalan; Juan Jose Badimon; Louis Aledort
Journal:  J Immunol Methods       Date:  2017-07-29       Impact factor: 2.303

7.  Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype.

Authors:  A D Blann; J S Mohan; D Bareford; G Y H Lip
Journal:  J Thromb Thrombolysis       Date:  2007-12-14       Impact factor: 2.300

8.  Clinical significance of assessment of thrombospondin and placenta growth factor levels in patients with sickle cell anemia: two centers egyptian studies.

Authors:  Adel A Hagag; Ghada Elmashad; Aml Ezzat Abd El-Lateef
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-07-01       Impact factor: 2.576

Review 9.  Phytomedicines and nutraceuticals: alternative therapeutics for sickle cell anemia.

Authors:  Ngozi Awa Imaga
Journal:  ScientificWorldJournal       Date:  2013-02-14

10.  Expression of regulatory platelet microRNAs in patients with sickle cell disease.

Authors:  Shilpa Jain; Maria G Kapetanaki; Nalini Raghavachari; Kimberly Woodhouse; Guoying Yu; Suchitra Barge; Claudia Coronnello; Panayiotis V Benos; Gregory J Kato; Naftali Kaminski; Mark T Gladwin
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.